Form 4: Immunocore Director Acquires Share Options
SEC Form 4 Filing
Director John Irving Bell acquired share options in Immunocore Holdings plc on May 23, 2024.
Summary
- On May 23, 2024, John Irving Bell, a director of Immunocore Holdings plc, acquired 14,534 share options.
- The exercise price of these options is $50.47.
- The options vest on the earlier of May 23, 2025, or the day before the next annual general meeting, contingent upon continuous service.
- The options expire on May 22, 2034.
- Following the transaction, Bell directly owns 14,534 derivative securities.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to the market regarding the holdings and transactions of company directors. It's a standard practice for publicly traded companies and their insiders.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding director's holdings.
Key Dates
| Date | Description |
|---|---|
| 05/23/2024 | Date of transaction: Director acquired share options. |
| 05/23/2025 | Earliest vesting date for the share options. |
| 05/22/2034 | Expiration date for the share options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.